FDA Approved -- Scenesse MC1R Agonist -- Tanning Safer Profile than Melanotan II

Melanotan I

Afamelanotide · Scenesse · [Nle4,D-Phe7]-alpha-MSH · CUV1647

"The FDA-approved tanning peptide -- alpha-MSH analogue that selectively activates MC1R to increase melanin production without the sexual side effects of Melanotan II (which hits MC4R). Approved as Scenesse for erythropoietic protoporphyria (EPP), a rare condition where sunlight causes extreme pain. Used off-label for photoprotection and tanning by the community."

FDA Status
Approved -- Scenesse (afamelanotide) for EPP 2019
Target
MC1R selective -- no MC4R sexual effects
vs Melanotan II
No libido/erection effects -- tanning only
Form
SubQ implant (Scenesse) or injection (off-label)
WADA
Not prohibited
Origin & Background

The approved tanning peptide -- and the safer story

Melanotan I (afamelanotide) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH) -- the endogenous peptide that regulates skin pigmentation. Developed at the University of Arizona in the 1980s alongside Melanotan II, the two peptides were designed to increase melanin production for UV protection. Where Melanotan II is a broad melanocortin receptor agonist hitting MC1R, MC3R, MC4R, and MC5R, Melanotan I (afamelanotide) is far more selective for MC1R specifically.

This receptor selectivity is the key clinical distinction. MC4R activation is responsible for the sexual arousal, spontaneous erections, and libido effects that characterise Melanotan II. By not significantly activating MC4R, afamelanotide produces pigmentation without these side effects -- making it suitable for medical use in a broader population including women, men who do not want sexual side effects, and clinical settings where Melanotan II would be inappropriate.

Afamelanotide (Scenesse) was approved by the FDA in October 2019 for erythropoietic protoporphyria (EPP) -- a rare genetic condition where a defect in haem biosynthesis leads to accumulation of protoporphyrin IX, making sunlight exposure intensely painful and causing life-altering photosensitivity. Scenesse is administered as a subcutaneous bioresorbable implant (16mg) that slowly releases afamelanotide over ~60 days, increasing melanin production and providing photoprotection that dramatically reduces EPP patients'' pain episodes. Clinical trials showed a 64% reduction in phototoxic reactions versus placebo.

The community uses injectable afamelanotide off-label for tanning and UV photoprotection -- the same mechanism as Scenesse but at lower doses and via injection rather than implant. The FDA approval provides important validation that the mechanism is real and the compound has an acceptable clinical safety profile.

Science & Mechanism

MC1R selective -- melanin without the side effects

Mechanism of Action

1
MC1R agonism -- melanogenesis: Afamelanotide binds MC1R on melanocytes with high affinity and selectivity. MC1R activation triggers adenylyl cyclase --> cAMP --> PKA --> MITF (microphthalmia-associated transcription factor) --> upregulation of tyrosinase and TYRP1/TYRP2 (melanin synthesis enzymes). The result: increased eumelanin (brown/black melanin) production, which provides UV protection by absorbing and scattering UV radiation.
2
Eumelanin vs phaeomelanin: MC1R activation shifts the melanin type from phaeomelanin (red/yellow, provides less UV protection, may actually increase oxidative DNA damage under UV) toward eumelanin (brown/black, absorbs UV, provides genuine photoprotection). This shift is the therapeutic mechanism in EPP and the cosmetic mechanism for tanning. Fair-skinned individuals with naturally high phaeomelanin-to-eumelanin ratios benefit most.
3
No MC4R activation -- no sexual effects: The structural modifications in afamelanotide (most notably [Nle4,D-Phe7] substitutions) provide selectivity for MC1R. Unlike Melanotan II, afamelanotide does not significantly activate MC4R in the hypothalamus -- the receptor responsible for Melanotan II''s sexual arousal and erection-inducing effects. This makes afamelanotide a pigmentation-specific compound.
4
Sustained release from implant (Scenesse): The approved Scenesse formulation is a bioresorbable poly(DL-lactide-co-glycolide) implant that releases afamelanotide over approximately 60 days. This provides sustained MC1R stimulation for continuous melanin upregulation over the summer photoprotection window for EPP patients -- a clinically practical sustained-release approach.
5
Injectable off-label pharmacokinetics: Community injection of afamelanotide produces a peak-and-trough plasma profile rather than the sustained release of the implant. Most users report visible pigmentation effects within 3-5 days of first injection, with peak tanning at 7-14 days. The duration depends on dose and individual melanocyte response.
Community Voices

What people report

Tanning ProtocolOff-label use -- not FDA-approved for this indication

Switched from Melanotan II to afamelanotide after finding the erection/libido effects of MT2 disruptive. MT1 produces an excellent tan with zero sexual side effects -- exactly what I wanted. The pigmentation quality is also more natural-looking (less grey undertone than MT2). Slower to start than MT2 but more controllable.

Male, 31. The comparison between the two melanotans is the most common context for afamelanotide use. The absence of MC4R effects is the primary reason people choose MT1. The slower onset is a consistent observation -- MT2 activates multiple receptors simultaneously for faster visible pigmentation; MT1 works purely via MC1R-driven melanogenesis.

EPP Patient ReportFDA-approved Scenesse

I have EPP and have been on Scenesse implants since 2020. Before Scenesse, 10 minutes in sunlight would cause burning pain for hours. On Scenesse I can spend 2-3 hours outside during summer with minimal symptoms. Life-changing is not an exaggeration.

Female, 28, EPP patient. EPP is a genuinely debilitating condition that profoundly restricts quality of life. Scenesse''s 64% reduction in phototoxic reactions in clinical trials represents one of the most meaningful QoL improvements of any rare disease treatment. This FDA-approved indication is the strongest validation of the afamelanotide mechanism.

Safety First

Safety -- FDA-approved means real data

🛡
FDA-approved with well-characterised safety profile from clinical trials and post-marketing surveillance. The absence of MC4R activity eliminates most of Melanotan II''s significant adverse effects. The principal monitored concern is skin pigmentation changes and nevi monitoring.
Mild
Nausea and injection site reactions -- most common adverse events in clinical trials. Nausea typically resolves within hours. Injection site bruising and swelling with SubQ administration.
Moderate
Nevi (mole) darkening and new nevi -- afamelanotide stimulates melanocytes broadly. Existing nevi can darken and become more irregular. New nevi can develop. Dermatological monitoring (dermoscopy annually) is recommended for anyone using afamelanotide regularly. Any rapidly changing lesion warrants immediate dermatological assessment.
Mild
Flushing and fatigue -- transient, dose-dependent. Less severe than with Melanotan II. Usually resolves within hours of administration.
Honest Assessment

Editor''s summary

Afamelanotide (Melanotan I) is the intellectually cleaner tanning peptide -- selective MC1R agonism delivers the pigmentation benefit without the MC4R-mediated sexual side effects that make Melanotan II difficult to use in many contexts. The FDA approval for EPP is clinically meaningful validation of both the mechanism and the safety profile. The difference between the two melanotans is not one of degree but of type -- MT1 is a tanning peptide; MT2 is a tanning + sexual arousal peptide.

For users who want the UV protective and cosmetic tanning effect of the melanotans without the sexual side effects -- and particularly for women, for whom Melanotan II''s effects are often unwanted or uncomfortable -- afamelanotide is the appropriate choice. The nevi monitoring recommendation should be taken seriously and is not optional.

Verdict
"The safe, FDA-approved melanocyte peptide -- tanning without erections. MC1R selective. Clinical validation for EPP. The natural choice for anyone wanting the UV protection and cosmetic pigmentation effects of the melanotans without Melanotan II''s sexual side effects. Annual dermatological monitoring non-negotiable."